1. Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study
- Author
-
Faris G. Bakri, Heyam H. Mukattash, Hiam Esmeiran, Glenna Schluck, Casey K. Storme, Erica Broach, Tsedal Mebrahtu, Mohammad Alhawarat, Anais Valencia-Ruiz, Oussama M'Hamdi, Jennifer A. Malia, Zebiba Hassen, Mah'd M.S. Shafei, Ala Y. Alkhatib, Mahmoud Gazo, Saied A. Jaradat, Yessenia Gomez, Samantha McGeehon, Melanie D. McCauley, Sarah C. Moreland, Janice M. Darden, Mihret Amare, Trevor A. Crowell, Sandhya Vasan, Nelson L. Michael, Julie A. Ake, Kayvon Modjarrad, Paul T. Scott, Sheila A. Peel, and Shilpa Hakre
- Subjects
HIV ,Jordan ,Molecular epidemiology ,Antiretroviral resistance ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: Limited epidemiologic studies have been conducted in Jordan describing the HIV epidemic. This study aimed to address this gap to inform HIV prevention and control. Methods: A nationally-representative cross-sectional study was conducted among adults living with HIV in Jordan. Laboratory testing included HIV viral load and next-generation-sequencing-based clinical genotype. Log-binomial regression estimated risk ratios (RRs) and 95% confidence intervals (CIs). Results: Among 231 (70%) participants, most were male (184/80%), and from Jordan (217/94%). Among 188 treatment-experienced-participants (>6 months), 165 (88%) were virally suppressed. High-level resistance was most frequent against nucleoside reverse transcriptase inhibitor (13/81%), and integrase-strand transfer inhibitor (INSTI) (10/62%) drugs among viremic (≥1000 HIV copies/mL) treatment-experienced participants with drug-resistant mutations (DRMs, n = 16). Common HIV subtypes (n = 43) were B (6/14%), A1 (5/12%), and CRF01_AE (5/12%); additionally, novel recombinant forms were detected. In multivariate analysis, independently higher risk for late diagnosis (n = 49) was observed with diagnosis through blood donation (vs check-up: RR 2.20, 95%CI 1.16-4.17) and earlier time-period of diagnosis (1986-2014 vs 2015-2021: RR 2.87, 95%CI 1.46-5.62). Conclusions: Late diagnosis and INSTI resistance endanger national HIV prevention and treatment in Jordan—high-level resistance to INSTI suggests therapeutic drug monitoring is needed for treatment efficacy and conservation of treatment options.
- Published
- 2024
- Full Text
- View/download PDF